Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon-Alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Gastroenterology

Volumn 149, Issue 6, 2015, Pages 1462-1470

  Foster, Graham R ^a   Pianko, Stephen ^b   Brown, Ashley ^c   Forton, Daniel ^d   Nahass, Ronald G ^e   George, Jacob ^f   Barnes, Eleanor ^g   Brainard, Diana M ^h   Massetto, Benedetta ^h   Lin, Ming ^h   Han, Bin ^h   McHutchison, John G ^h   Subramanian, G Mani ^h   Cooper, Curtis ⁱ   Agarwal, Kosh ^j  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SOUTHERN HEALTH   (Australia)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e ID Care   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h GILEAD SCIENCES   (United States)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

BOSON; Hepatitis C Virus; Nucleotide Analog; Peginterferon

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA AND NEW ZEALAND; CHILL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EUROPE; FAINTNESS; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NORTH AMERICA; OPEN STUDY; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THORAX PAIN; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING; AGED; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PATHOGENICITY; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; SOFOSBUVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84943558459     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.043     Document Type: Article

References (15)

1. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: www.hcvguidelines.org. Accessed June 16, 2015.
2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. Available at: http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf. Accessed June 16, 2015.
3. J.P. Messina, I. Humphreys, A. Flaxman, and et al. Global distribution and prevalence of hepatitis C virus genotypes Hepatology 61 2015 77 87
4. F. Kanwal, J.R. Kramer, J. Ilyas, and et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV Hepatology 60 2014 98 105
5. N. Goossens, and F. Negro Is genotype 3 of the hepatitis C virus the new villain? Hepatology 59 2014 2403 2412
6. E. Lawitz, A. Mangia, D. Wyles, and et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
7. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, and et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
8. S. Zeuzem, G.M. Dusheiko, R. Salupere, and et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
9. D.R. Nelson, J.N. Cooper, J.P. Lalezari, and et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study Hepatology 61 2015 1127 1135
10. E.J. Gane, R.H. Hyland, D. An, and et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection Gastroenterology 149 2015 1454 1461
11. E. Lawitz, F. Poordad, D.M. Brainard, and et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis Hepatology 61 2015 769 775
12. E. Svarovskaia, H. Dvory-Sobol, N. Parkin, and et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials Clin Infect Dis 59 2014 1666 1674
13. J.C. Price, and N.A. Terrault Treatment of hepatitis C in liver transplant patients: interferon OUT, direct antiviral combos IN Liver Transpl 21 2015 423 434
14. K.J. Cortez, and S. Kottilil Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C Ther Adv Chronic Dis 6 2015 4 14
15. A.H. Yau, and E.M. Yoshida Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review Can J Gastroenterol Hepatol 28 2014 445 451